I think the reason is th at these competitive reactions are delicately balanced and can only operate under highly controlled conditions.
If you design an analogue on the model of substance A , you readily obtain inhibi tion in the test-tube when you add a sufficient concentration of the analogue to compete with any of the substance A which the microbe can synthesize. In the fluid phases of animal blood however, where the bacteria are situated, there may be alreadv such a concentration of A that you cannot compete with it and the bacteria will continue to grow.
Further, in the test-tube you may inhibit the use of substance A so th at the next component B cannot be synthesized, but if you add mere traces of B, the competi tion with A is entirely ineffective in preventing growth. The synthesis continues from B. B may be present in the liquid phases of the blood. Thus, until you know the concentration of growth factors in the blood, your chances of selecting the most suitable growth factor as a model for your analogue are small. At present we have not this information.
Furthermore, on the chemical side, it seems desirable th at more system should be used in the design of analogues. It is found that when one and the same substitution is made in different positions in a growth-factor molecule, the effect is quantitatively different. In this case it may be possible to deduce something about the mechanisms
Introduction
The object of the present communication is to give a broad outline of what is known concerning the antibiotic activity of growth-factor analogues, and to provide a background for the more detailed communications which follow. At the same time opportunity will be taken to fill in briefly unavoidable gaps between these communi cations ; there are now so many aspects of the subject which have received attention that a full discussion would be impossible in the time available. For the same reason it will not be possible to give detailed references to the literature but only to reviews and certain selected recent papers.
The main concept under discussion is that the growth of micro-organisms may be inhibited by substances of related chemical constitution to factors which are essen tial for their growth. The discovery of the relationship of p-aminobenzoic acid (an essential metabolite) to the mode of action of the sulphonamides focused attention on this concept and has stimulated much new experimental work. The phenomenon of competitive inhibition of enzyme reactions by substances chemically related to the substrate was well established when the biological importance of ^-aminobenzoic acid was first realized, and was, indeed, of fundamental importance for th at discovery. The classical example is that of the competitive inhibition by malonate of the oxidation of succinate by the succinic dehydrogenase enzyme system. The phenomenon is explained in terms of general accepted enzyme kinetic theory as follows:
An initial combination of the enzyme E and substrate S results in activation of the complex formed ES and is followed by decomposition of the complex with liberation of the enzyme and the products of substrate metabolism X, The inhibitor M by virtue of its structural similarity to the substrate is envisaged as being able also to enter into combination with the enzyme. This combination does not, however, result in activation and consequently there is no decomposition of M. In the presence of both S and M, the overall rate of the enzyme reaction will thus depend on the relative rates of the reversible reactions (1) and (2), and therefore, for a given pair of compounds, upon their relative concentrations; the two substances, in effect, compete for the available enzyme (Haldane 1930).
Mode of action of sulphonamides
Extracts of many tissues are able to overcome the growth-inhibitory action of the sulphonamides. Strong evidence was obtained th at the activity of yeast extracts in this respect is due to p-aminobenzoic acid, and this substance itself overcomes the effect of the sulphonamides in a competitive manner, i.e. there is a strict quantita tive relationship between the concentration of drug used and the concentration of p-aminobenzoic acid required. This relationship, taken in conjunction with (a) the similarity in chemical structure between the antagonist and the parent drug, sulphanilamide, and (6) the high intrinsic activity ofp-aminobenzoic acid (one mole cule antagonizes c. 10,000 molecules of sulphanilamide), led directly to a working hypothesis concerning the fundamental mode of action of the sulphonamides. It was suggested that p-aminobenzoic acid is an essential substance for the growth of bacteria, and th at sulphonamides, by virtue of their chemical similarity, inhibit competitively the enzyme system involved in the utilization of this substrate. In the terminology of the last section p-aminobenzoic acid would be S and the sulphon amides would be M. The hypothesis has received its most important confirmation from the fulfilment of the prediction th at p-aminobenzoic acid is an essential metabolite for bacteria; it has been shown to be an essential growth factor (i.e. an external source is needed) for the growth of some fifteen different species of bacteria, yeast and moulds. Bacteria not needing an external supply are shown to synthesize it for themselves. The sulphonamide/p-aminobenzoic acid relation is of very general application both in respect to (a) the test organism and (6) the particular sulphon amide used (of the general type NH2-C6H4. S 0 2N H jR), the only exceptions being (a) Bad. tularense, (b) sulphanilylanilides. This, and other evidence which cannot be dealt with here, provide more than sufficient support to warrant the retention of the hypothesis as a basis for further work. The form of the hypothesis outlined envisages p-aminobenzoic acid as the substrate of the enzyme; similar relationships would, of course, also exist if this substance were a co-enzyme or prosthetic group whose combination with the enzyme was subject to competition by sulphonamid.es.
For a fuller understanding of the biochemical mode of action of the sulphonamides the next step is to discover the nature of the products of the reaction in which p-aminobenzoic acid is involved either as substrate or possibly as co-enzyme. Considerable evidence is now to hand that p-aminobenzoic acid functions either directly or indirectly in the biosynthesis of (a) folic acid, ( purines, (c) the pyri midine, thymine and ( d) certain amino-acids (methionine, serine, lysine and others). In the case of folic acid the function is direct; in the other cases it appears to be indirect, and evidence for these functions is based largely on findings th at these substances, either singly or in various mixtures, may replace p-aminobenzoic acid, either wholly or in part, both in respect of its function as a growth factor and as an anti-sulphonamide agent. There is some evidence (from replacement experi ments with organisms requiring folic acid) that the function in the synthesis of the nucleic acid derivatives occurs through folic acid. If all the substances in whose synthesis p-aminobenzoic acid is concerned are provided preformed in the medium, two things would be expected (provided the substances can be absorbed by the cell): (a) organisms requiring p-aminobenzoic acid should grow in the absence of this factor, (6) all organisms should be insensitive to sulphonamides since the products of the inhibited reactions have been already given.
Folic acid is another essential metabolite (one of the vitamin B group of factors) both for micro-organisms and for higher animals (see review by Jukes & Stokstad 1948) . A direct role of p-aminobenzoic acid in the biosynthesis of this factor has been made clear by the elucidation of the structure, and synthesis of, one member of the folic acid group of vitamins ( L a c t o b a c i l l u sc a se i factor). This compound (pter glutamic acid) is A-[4-{[(2-amino-4-liydroxy-6-pteridyl) methyl] amino} benzoyl] glutamic acid; it thus contains a p-aminobenzoic acid residue linked through the amino-group to a pteridin residue and through the carboxylic-group to glutamic acid. I t is therefore likely that p-aminobenzoic acid is one of the substances required for its biosynthesis. There is now direct evidence th at the synthesis of Lb. casei factor by cells of Lb. plantarum, under conditions in which no growth occurs, depends quantitatively on the presence of p-aminobenzoic acid, and th at the synthesis is inhibited competitively by the sulphonamides.
With some organisms there is good evidence th a t the only function of p-aminobenzoic acid may be its requirement for folic acid synthesis, and th at inhibition of this reaction represents the main point of attack of sulphonamides on the cell. Organisms requiring folic acid itself as growth factor have been found to be almost insusceptible to inhibition by sulphonamides; this would be expected, since the metabolic lesion presumed to be induced by sulphonamides already exists and the product of the inhibited reaction must be added to obtain growth even without sulphonamides. Certain enterococci for which folic acid is stimulatory though not essential (indicating that the rate of synthesis of this factor is limiting growth) are highly susceptible to sulphonamides in the absence of folic acid, but again almost completely insensitive in its presence. Finally, with some organisms (but not all) which require p-aminobenzoic acid for growth it has been found that pteroyl-glutamic acid can replace this factor, although a higher molar concentration is required, and th at growth is not inhibited by sulphonamides over a wide range of concentration in the presence of pteroylglutamic acid at the concentration in which it is effective in replacing p-aminobenzoic acid for growth. It should be remarked th at in many cases (though not all) the basal media for the above organisms contained nucleic acid derivatives and amino-acids, since these are known to be essential for some of the organisms irrespective of the requirement for p-aminobenzoic acid or folic acid.
W ith regard to other organisms th at have been tested (e.g. several other species for which p-aminobenzoic acid is a growth factor, also several species not requiring an external source of this factor or of folic acid) the position is apparently quite different. Synthetic pteroylglutamic acid appears to act only as an inefficient source of p-aminobenzoic acid; sulphonamide inhibition is antagonized, if at all, in a competitive manner. This m atter cannot be considered in detail here, but it may be said th at there is evidence, from observations of the growth factor and antisulphonamide action of various mixtures of nucleic acid derivatives, amino-acids and pteroylglutamic acid, th at in such organisms p-aminobenzoic acid may function indirectly in the synthesis of all these substances, and th at all these functions are subject to inhibition by sulphonamides. It cannot yet be decided whether the mechanism is quite different in these various syntheses or whether folic acids not identical with synthetic pteroylglutamic acid may be intermediates.
For full details of the work described in this section reference may be made to the reviews of Henry (1944) , Roblin (1946 ), Woolley (1947 , Work & Work (1948) and Woods (1949) .
The therapeutic value of the sulphonamides is due to their toxicity to the in vading microbes and relative lack of toxicity to the host. The work outlined above provides some explanation for this difference. Folic acid is also an essential metabolite for mammals, and the available evidence indicates th at no simpler compound than folic acid will serve. The animal therefore resembles those bacteria which require preformed folic acid and would be relatively insensitive to sulphon amides for the same reasons. This m atter is discussed in more detail by Woolley (1947) and by Woods & Nimmo-Smith (1949) .
A rational approach to research in chemotherapy
The discovery of the relationship between p-aminobenzoic acid and sulphon amides, providing as it did a rational explanation in biochemical terms of the mode of action of these drugs, stimulated a search for analogues of other known bacterial growth factors which might inhibit growth for the same reasons. This concept was enunciated by Fildes (1940) in his paper on 'a rational approach to research in chemotherapy'. Since then a very large number of substances of this type have been found which inhibit specifically the growth of micro-organisms, i.e. their action is overcome by the growth factor on which they are modelled (see reviews by Roblin (1946) and Woolley (1947) . Only very few, however, have shown any promise of being useful therapeutic agents, and these are all analogues of panto thenic acid-a point th at merits further research. I t should be emphasized that this approach can only predict substances likely to have anti-bacterial activity; it cannot predict, for example, whether they will be suitable from the point of view of absorption, excretion or possibly destruction by the host tissues. Another difficulty is that success as a therapeutic agent implies selective toxicity against the invading microbe. Many of the compounds made have been analogues of substances (B-group vitamins, amino-acids) which are well known to be equally essential for the meta bolism of host tissues; indeed, these analogues have often been found to induce in the host specific deficiency symptoms of the vitamin in question. This is a major difficulty in view of the fundamental similarity of basic reactions in all types of cells. W hat are needed are analogues of factors essential only for bacterial growth, and Dr Work will suggest later an interesting and promising approach to this problem. Another possible solution which has been suggested (Roblin 1946) is to concentrate upon analogues of factors (as these become known) which are concerned with anabolic processes of the cell. Even if these are not selective against bacteria it is possible that a short-term interruption to such processes may do relatively little harm to the adult host in which rapid cell proliferation occurs in a few tissues only; at the same time bacterial growth might be held in check sufficiently long to permit the normal defence mechanisms of the host to deal with the situation.
The recent studies on the p-aminobenzoic acid/sulphonamide relationship make it clear th at a detailed knowledge of the function of a growth factor in cell m eta bolism may be of considerable aid in evaluating the possible therapeutic value of the analogue. Dr Mcllwain will review our knowledge concerning the point of action of some other analogue inhibitors in cell metabolism.
Finally, it must be realized that in the past the design of these growth inhibitors has often been based on rather ' pictorial ' considerations of the chemical structure of the growth factor and related substances. Dr Rydon will illustrate the value of more fundamental considerations of chemical structure, especially in relation to what specific chemical grouping are involved in the union of the substrate with the enzyme.
Possible anti-metabolite action of other growth inhibitors
There is some evidence th at the activity of a few other substances which inhibit growth of micro-organisms (including two natural antibiotics) may be due to com petition with metabolites. I t must be strongly emphasized th at the evidence is never more than suggestive, and that the cases quoted must be considered at the present only as interesting possibilities.
Dr Rose will examine such possibilities in the case of some of the anti-malarial drugs, including paludrine. Another synthetic drug which has been considered as possibly acting in this way is the insecticide 'Gammexane' (y-hexachlorocyclohexane). Slade (1945) pointed out th at the stereochemical configuration of the y-isomer was probably analogous to that of meso-inositol (which is known to be a growth factor for yeast and other micro-organisms), and he suggested th at Gammexane' may act on insects by an effect on inositol metabolism. This idea received support from the observation of Kirkwood & Phillips (1946) th at 'Gam mexane but not the other isomers, inhibited the growth of a yeast which required inositol, and that such inhibition was overcome by increasing the inositol concen tration in the medium. But this is not the case with all micro-organisms; with Tetrahymena geleii and with a number of bacteria it has been found that cbhexachlorocyclohexane is more inhibitory than the y-isomer, and that in neither case is inhibition overcome by inositol (Chaix, Lacroix & Fromageot 1948; Fromageot & Confino 1948) .* There is an interesting observation of Rhymer, Wallace, Byers & Carter (1947) which suggested to them the possibility of an anti-metabolite activity of strepto mycin. Inhibition of the growth of Staphylococcus aureus was overcome by purified preparations of lipositol; the amount needed was in the proportion 1 lipositol/300 streptomycin. Lipositol is a phospholipoid obtained first from brain and later from soy-bean; its structure is not yet fully worked out, but it is an inositol derivative containing, amongst other substituents, a galactose residue (Woolley 1943) . Streptomycin is also an inositol derivative containing carbohydrate residues. There is, of course, no evidence that lipositol is an essential metabolite for bacteria, but only th at it is of natural occurrence; its detection in nerve tissue is of interest in view of the toxic action of streptomycin on the V U Ith nerve.
Lycomarasmin is an antibiotic produced by Fusarium and is respon sible for the tomato-wilt effect of this fungus; it also inhibits the growth of bacteria. Woolley (for references see Woolley 1948 a) followed up earlier work on the chemical nature of this compound and found th at seryl-glycyl-aspartic acid had considerable lycomarasmin activity. At the same time he and his collaborators were working on a growth stimulant (strepogenin) for certain streptococci and lactobacilli, and obtained evidence that it was probably a peptide containing glutamic acid. Con centrates overcame the antibiotic effect of lycomarasmin on both tomato plants and bacteria. Applying the analogue-inhibitor concept Woolley therefore synthesized (amongst other peptides) seryl-glycyl-glutamie acid. This had strepogenin activity in all respects though it cannot be strepogenin itself, since it had only 2*5 % of the activity of the most purified preparations of the natural factor.f
Metabolite analogues as tools in fundamental research
In the case of lycomarasmin just discussed the concept of inhibition by growthfactor analogues has led to some valuable information concerning the chemistry of the growth factor concerned. It would be a pity to consider these analogue inhibitors only as potential therapeutic agents; they have also proved to be valuable tools in * Since this discussion was held, van Vloten, Kruissink, Strijk & B ijvoet (1948) have shown by an X -ray analysis of th e crystal stru ctu re of 'G am m exane' th a t it is not isomorphous with meso-inositol.
t Since this discussion was held Woolley (19486) has obtained strong evidence th a t the stru ctu re of lycom arasm in is OH H
CH3C-NH-CH2-CO-NH-C-CH2CO. NH2 io o H COOH
The synthesis and testing for strepogenin activity of the corresponding analogue containing a glutam ine rath er th an an asparagine residue will be of great interest.
helping to elucidate the function of growth factors and vitamins in cell metabolism. They act as rather specific inhibitors of the utilization or synthesis of the analogous factor and thus provide a means of tracing the primary effect of th at factor. Suppose that the biosynthesis of some essential substance Z occurs in the following stages:
and that a factor F is involved in one of these stages. Competitive inhibition of the function of F by an analogue FA will block the reaction sequence and growth will not occur. Theoretically inhibition may be overcome by adding an extra supply of F or by giving the products (T or Z )w diich are beyond the block. O must serve to illustrate this point. Shive & Rogers (1947) have found th at 3, 4-urylenecyclohexylbutyric acid, an analogue of biotin, inhibits the growth of Lactobacillus arabinosus (an organism requiring biotin). Inhibition is reversed competitively by biotin, thus establishing the specificity of the effect. The amount of biotin required is, however, reduced tenfold if oxaloacetic acid is present, and this suggests th at one function of biotin is concerned with the synthesis of this keto-acid; evidence derived from other studies indicates th at this synthesis probably occurs through the condensation of C0 2 and pyruvic acid.
Analogue inhibitors as growth factors
It sometimes happens th at a given substance may act as growth inhibitor for one organism and as growth factor for another organism or variant of the same organism. Two such cases maybe quoted from the growth-factor analogues; in one case there is a simple explanation, in the other, not. Desthiobiotin can replace biotin for the growdh of yeast; the organism can complete the synthesis from this compound, which may indeed be a normal intermediate, the requirement of such yeasts for biotin being due to a failure at an earlier stage of the reaction sequence. Lb. casei, on the other hand, is unable to convert desthiobiotin to biotin, and here the former acts as an inhibitory analogue, prevents the utilization of biotin and thus suppresses growth.
Emerson (1947) has studied some interesting variants of Neurospora. One of these, obtained by crossing a sulphonamide-resistant strain with the wild type, actually has an essential requirement for sulphonamide for growth at temperatures above 30°; the effect is less marked at lower temperatures. I t seems probable th at p-aminobenzoic acid remains an essential metabolite; by crossing this variant with a m utant requiring p-aminobenzoic acid a variant was obtained which requires both this substance and sulphonamide. p-Aminobenzoic acid inhibits the sulphonamidepromoted growth of these organisms, but it is interesting th at the critical ratio between the two substances remains the same whichever is acting as growth factor.
Miscellaneous
One further interesting application of the general concept of biological antagonism between analogues may be mentioned. Green & Woolley (1947) followed up a sug gestion of Hirst (1942) that the agglutination of red cells by influenza virus may be due to an enzymic attack on a specific substrate, probably of a polysaccharide nature, in the cell. They therefore tried the effect of a number of polysaccharides on the reaction. Several of these, particularly apple pectin, inhibited haemagglutinatio n ; furthermore, the apple pectin also inhibited multiplication of the virus in egg embryo.
In conclusion, it should be stressed that a complete understanding of the function of individual essential metabolites in cell metabolism, and of the comparative specificity of requirement by host and micro-organism, is one of the essentials for a profitable exploitation of growth-factor analogues as potential chemotherapeutic agents. And the analogues themselves are proving to be valuable tools in such fundamental investigations whether or not they are themselves useful as thera peutic agents. Functional relations between analogue and growth factor Evidence connecting the action of an analogue with its parent growth factor is of three main types.
I. Antagonism in action
This can be the clearest of all types of evidence; it has been much discussed, classified, and subjected to mathematical expression. For th at reason I will say most about other types of evidence, and make only two observations concerning this first category, (a) The antagonism can be observed at various levels: that of an overall biological effect such as growth, or a t th at of an individual enzymic T a b l e 1. System s in w h ic h a n ta g o n ism b e t w e e n p a n t o t h e n ic acid (I) AND PANTOYLTAURINE (II) HAS BEEN OBSERVED 1. C hem otherapeutic: protection of infected r a t from haem olytic streptococci. 2. Microbiological: streptococcal growth. 3. A series of enzyme reactions: resulting in assim ilation of pantothenate to growing strepto cocci. 4. A simpler enzyme system : resulting in inactivation of pantothenate by non-proliferating streptococci during glycolysis. 
